Aptargroup Stock Fair Value Calculator – APTARGROUP Reports Profitable Second Quarter Results for FY2023
August 3, 2023
☀️Earnings Overview
APTARGROUP ($NYSE:ATR) announced their earnings results for the second quarter of FY2023, which concluded on June 30 2023. Total revenue for the quarter amounted to USD 895.9 million, showing a 6.1% year-over-year growth. Net income rose by 30.6%, reaching USD 83.1 million compared to the same quarter of the previous year.
Stock Price
The company had a profitable second quarter, with its stock opening at $120.1 and closing at 119.1, down by 0.7% from the previous closing price of 120.0. The company’s earnings per share (EPS) was lower than expected, but the revenue was higher than expected. Overall, APTARGROUP had a successful second quarter for fiscal year 2023.
Their stock may have closed slightly lower than expected, but their EPS and revenue were higher than expected. The company is looking forward to continuing their growth for the remainder of the year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aptargroup. More…
| Total Revenues | Net Income | Net Margin |
| 3.39k | 251.08 | 7.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aptargroup. More…
| Operations | Investing | Financing |
| 484.16 | -320.13 | -279.31 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aptargroup. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.35k | 2.16k | 33.19 |
Key Ratios Snapshot
Some of the financial key ratios for Aptargroup are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.7% | 5.1% | 11.3% |
| FCF Margin | ROE | ROA |
| 4.7% | 11.2% | 5.5% |
Analysis – Aptargroup Stock Fair Value Calculator
At GoodWhale, we recently conducted an analysis of APTARGROUP‘s wellbeing. Through our proprietary Valuation Line, we have determined that APTARGROUP’s intrinsic value is around $123.3. Currently, APTARGROUP’s stock is being traded at $119.1, which is a fair price that is undervalued by 3.4%. This provides investors with an opportunity to purchase a great company at a discounted rate. More…
Peers
The competition between AptarGroup Inc and Sonova Holding AG, Bruker Corp, West Pharmaceutical Services Inc is fierce. Each company is striving to be the best in the industry, and they are all constantly innovating and improving their products and services. This competition is good for consumers, as it drives down prices and forces the companies to be at the top of their game.
– Sonova Holding AG ($LTS:0QPY)
Sonova Holding AG is a world leader in providing solutions for people with hearing loss. The company has a market capitalization of 14.2 billion as of 2022 and a return on equity of 27.55%. Sonova’s products and services are available in more than 100 countries and include cochlear implants, hearing aids, wireless communication systems, and software applications. The company’s mission is to provide people with the best possible hearing solutions and to enable them to lead fulfilling lives.
– Bruker Corp ($NASDAQ:BRKR)
Bruker Corporation is a leading manufacturer of scientific instruments and solutions. The company produces a wide range of products for a variety of applications, including healthcare, industrial and scientific research, and security. Bruker’s products are used by customers around the world, and the company has a strong presence in both developed and emerging markets. The company’s market capitalization is 8.14 billion as of 2022, and its return on equity is 29.41%. Bruker is a publicly traded company, and its shares are listed on the Nasdaq Stock Market.
– West Pharmaceutical Services Inc ($NYSE:WST)
West Pharmaceutical Services Inc is a leading manufacturer of pharmaceutical packaging components and delivery systems. The company has a market cap of 18.33B as of 2022 and a Return on Equity of 20.68%. West Pharmaceutical Services Inc is a global leader in the design and manufacture of innovative, high-quality pharmaceutical packaging components and delivery systems. The company’s products are used by pharmaceutical, biotechnology and healthcare companies to improve patient safety and outcomes.
Summary
Investors have been pleased with APTARGROUP’s performance thus far in FY2023. Total revenue for the second quarter ended June 30, 2023, was USD 895.9 million, 6.1% higher than the same period in the prior year. Net income increased by 30.6%, reaching USD 83.1 million.
The company’s strong revenue and income growth has created a positive outlook for future potential profits and earnings. With an increasingly healthy balance sheet, APTARGROUP is well-positioned to further strengthen its competitive position in the market and to pursue other growth opportunities.
